Intrathecal Immunoglobulin for treatment of adult patients with tetanus: A randomized controlled 2x2 factorial trial

Huỳnh Thị Loan, Lam Minh Yen, Evelyne Kestelyn, Nguyen Van Hao, Tran Tan Thanh, Nguyen Thi Phuong Dung, Hugo C Turner, Ronald B Geskus, Marcel Wolbers, Le Van Tan, H Rogier Van Doorn, Nicholas P Day, Duncan Wyncoll, Tran Tinh Hien, Guy E Thwaites, Nguyen Van Vinh Chau, C Louise Thwaites, Huỳnh Thị Loan, Lam Minh Yen, Evelyne Kestelyn, Nguyen Van Hao, Tran Tan Thanh, Nguyen Thi Phuong Dung, Hugo C Turner, Ronald B Geskus, Marcel Wolbers, Le Van Tan, H Rogier Van Doorn, Nicholas P Day, Duncan Wyncoll, Tran Tinh Hien, Guy E Thwaites, Nguyen Van Vinh Chau, C Louise Thwaites

Abstract

Despite long-standing availability of an effective vaccine, tetanus remains a significant problem in many countries. Outcome depends on access to mechanical ventilation and intensive care facilities and in settings where these are limited, mortality remains high. Administration of tetanus antitoxin by the intramuscular route is recommended treatment for tetanus, but as the tetanus toxin acts within the central nervous system, it has been suggested that intrathecal administration of antitoxin may be beneficial. Previous studies have indicated benefit, but with the exception of one small trial no blinded studies have been performed. The objective of this study is to establish whether the addition of intrathecal tetanus antitoxin reduces the need for mechanical ventilation in patients with tetanus. Secondary objectives: to determine whether the addition of intrathecal tetanus antitoxin reduces autonomic nervous system dysfunction and length of hospital/ intensive care unit stay; whether the addition of intrathecal tetanus antitoxin in the treatment of tetanus is safe and cost-effective; to provide data to inform recommendation of human rather than equine antitoxin. This study will enroll adult patients (≥16 years old) with tetanus admitted to the Hospital for Tropical Diseases, Ho Chi Minh City. The study is a 2x2 factorial blinded randomized controlled trial. Eligible patients will be randomized in a 1:1:1:1 manner to the four treatment arms (intrathecal treatment and human intramuscular treatment, intrathecal treatment and equine intramuscular treatment, sham procedure and human intramuscular treatment, sham procedure and equine intramuscular treatment). Primary outcome measure will be requirement for mechanical ventilation. Secondary outcome measures: duration of hospital/ intensive care unit stay, duration of mechanical ventilation, in-hospital and 240-day mortality and disability, new antibiotic prescription, incidence of ventilator associated pneumonia and autonomic nervous system dysfunction, total dose of benzodiazepines and pipecuronium, and incidence of adverse events. Trial registration: ClinicalTrials.gov NCT02999815 Registration date: 21 December 2016.

Keywords: Tetanus; antitoxin; human tetanus immunoglobulin; intrathecal; management; treatment.

Conflict of interest statement

No competing interests were disclosed.

Figures

Figure 1.. Study flowchart.
Figure 1.. Study flowchart.

References

    1. Aceh Epidemiology Group: Outbreak of tetanus cases following the tsunami in Aceh Province, Indonesia. Glob Public Health. 2006;1(2):173–7. 10.1080/17441690600652803
    1. Kyu HH, Mumford JE, Stanaway JD, et al. : Mortality from tetanus between 1990 and 2015: findings from the global burden of disease study 2015. BMC Public Health. 2017;17(1):179. 10.1186/s12889-017-4111-4
    1. Thwaites CL, Yen LM, Nga NT, et al. : Impact of improved vaccination programme and intensive care facilities on incidence and outcome of tetanus in southern Vietnam, 1993-2002. Trans R Soc Trop Med Hyg. 2004;98(11):671–7. 10.1016/j.trstmh.2004.01.008
    1. Thuy DB, Campbell J, Hoang NVM, et al. : A one-year prospective study of colonization with antimicrobial-resistant organisms on admission to a Vietnamese intensive care unit. PLoS One. 2017;12(9):e0184847. 10.1371/journal.pone.0184847
    1. Phu VD, Wertheim HF, Larsson M, et al. : Burden of hospital acquired infections and antimicrobial use in Vietnamese adult intensive care units. PLoS One. 2016;11(1):e0147544. 10.1371/journal.pone.0147544
    1. Woldeamanuel YW, Andemeskel AT, Kyei K, et al. : Case fatality of adult tetanus in Africa: Systematic review and meta-analysis. J Neurol Sci. 2016;368:292–9. 10.1016/j.jns.2016.07.025
    1. Health Protection Agency: Tetanus: information for health professionals.2013.
    1. Miranda-Filho Dde B, Ximenes RA, Barone AA, et al. : Randomised controlled trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route. BMJ. 2004;328(7440):615. 10.1136/bmj.38027.560347.7C
    1. Wateba MI, Diop S, Nichols S, et al. : [Intrathecal therapy with 1 500 UI of antitetanic serum and 1.5 g of intravenous metronidazole: Prognosis of tetanus in hospitalized patients in Togo]. Sante. 2008;18(3):125–9. 10.1684/san.2008.0115
    1. Sun KO, Chan YW, Cheung RT, et al. : Management of tetanus: a review of 18 cases. J R Soc Med. 1994;87(3):135–7.
    1. Gupta P, Kapoor R, Goyal S, et al. : Intrathecal human tetanus immunoglobulin in early tetanus. Lancet. 1980;2(8192):439–40. 10.1016/S0140-6736(80)91883-8
    1. Agarwal M, Thomas K, Peter J V, et al. : A randomized double-blind sham-controlled study of intrathecal human anti-tetanus immunoglobulin in the management of tetanus. Natl Med J India. 1998;11(5):209–12.
    1. Sanchez GM, Burridge AL: Decision making in head injury management in the Edwin Smith Papyrus. Neurosurg Focus. 2007;23(1):E5. 10.3171/FOC-07/07/E5
    1. Sanders RKM, Peacock ML: Intrathecal antitetanus serum (horse) in the treatment of tetanus. Lancet. 1977;1(8019):974–7. 10.1016/S0140-6736(77)92278-4
    1. Thomas PP, Crowell EB, Jr, Mathew M: Intrathecal anti-tetanus serum (ATS) and parenteral betamethasone in the treatment of tetanus. Trans R Soc Trop Med Hyg. 1982;76(5):620–3. 10.1016/0035-9203(82)90224-3
    1. Geeta MG, Krishnakumar P, Mathews L: Intrathecal tetanus immunoglobulins in the management of tetanus. Indian J Pediatr. 2007;74(1):43–5. 10.1007/s12098-007-0025-y
    1. Narang M, Khurana A, Gomber S, et al. : Epidemiological trends of tetanus from East Delhi, India: A hospital-based study. J Infect Public Health. 2014;7(2):121–4. 10.1016/j.jiph.2013.07.006
    1. Ahmad A, Qaisar I, Naeem M, et al. : Intrathecal anti-tetanus human immunoglobulin in the treatment of neonatal tetanus. J Coll Physicians Surg Pak. 2011;21(9):539–41.
    1. Mongi P, Mbise R, Msengi A, et al. : Tetanus neonatorum--experience with intrathecal serotherapy at Muhimbili Medical Centre, Dar es Salaam, Tanzania. Ann Trop Paediatr. 1987;7(1):27–31. 10.1080/02724936.1987.11748469
    1. Abrutyn E, Berlin JA: Intrathecal therapy in tetanus. A meta-analysis. JAMA. 1991;266(16):2262–7. 10.1001/jama.1991.03470160094039
    1. Kabura L, Ilibagiza D, Menten J, et al. : Intrathecal vs. intramuscular administration of human antitetanus immunoglobulin or equine tetanus antitoxin in the treatment of tetanus: a meta-analysis. Trop Med Int Heal. 2006;11(7):1075–81. 10.1111/j.1365-3156.2006.01659.x
    1. Rodrigo C, Fernando D, Rajapakse S: Pharmacological management of tetanus: an evidence-based review. Crit Care. 2014;18(2):217. 10.1186/cc13797
    1. McCracken GH, Jr, Dowell DL, Marshall FN: Double-blind trial of equine antitoxin and human immune globulin in tetanus neonatorum. Lancet. 1971;1(7710):1146–9. 10.1016/S0140-6736(71)91659-X
    1. Centers for Disease Control and Prevention (CDC): Pink Book.Tetanus.1997;291–300.
    1. Loan HT, Parry J, Nga NT, et al. : Semi-recumbent body position fails to prevent healthcare-associated pneumonia in Vietnamese patients with severe tetanus. Trans R Soc Trop Med Hyg. 2012;106(2):90–7. 10.1016/j.trstmh.2011.10.010
    1. Common Terminology Criteria for Adverse Events.
    1. Thwaites CL, Yen LM, Glover C, et al. : Predicting the clinical outcome of tetanus: the tetanus severity score. Trop Med Int Heal. 2006;11(3):279–87. 10.1111/j.1365-3156.2006.01562.x
    1. Menon J, Mathews L: Intrathecal immunoglobulin in the treatment of tetanus. Indian Pediatr. 2002;39(7):654–7.
    1. Barlow JL, Mung’Ala-Odera V, Gona J, et al. : Brain damage after neonatal tetanus in a rural Kenyan hospital. Trop Med Int Heal. 2001;6(4):305–8. 10.1046/j.1365-3156.2001.00705.x
    1. Robert R, Rouffineau A, Cremault A, et al. : Robert 1984 IT. La Press Medicalle. 1984;13(32):1947–8.
    1. Lim ES, Lee IO: Effect of intrathecal glycine and related amino acids on the allodynia and hyperalgesic action of strychnine or bicuculline in mice. Korean J Anesth. 2010;58(1):76–86. 10.4097/kjae.2010.58.1.76
    1. Munts AG, van der Plas AA, Voormolen JH, et al. : Intrathecal glycine for pain and dystonia in complex regional pain syndrome. Pain. 2009;146(1–2):199–204. 10.1016/j.pain.2009.07.030
    1. Ibinda F, Bauni E, Kariuki SM, Fegan G, Lewa J, Mwikamba M, Boga M, Odhiambo R, Mwagandi K, Seale AC, Berkley JA, Dorfman JR, Newton CR: Incidence and risk factors for neonatal tetanus in admissions to Kilifi County Hospital, Kenya. PLoS One.2015;10(4) : 10.1371/journal.pone.0122606 e0122606 10.1371/journal.pone.0122606

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa